IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

The hand sanitizer spray pen market is projected to grow at a CAGR of 11% over the forecast period, reaching a market value ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

Seven independent members of the company’s board resigned Tuesday, concluding that despite co-founder and CEO Anne Wojcicki’s ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling ...

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Would-be dads taking drugs to stop their epilepsy seizures—and valproate in particular—should be largely reassured that the available evidence on the developmental risks to their offspring doesn’t ...